Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Fremanezumab efficacy and safety maintained over 1 year

Results of a 1-year multicentre, randomised, double-blind, parallel-group study showed sustained effectiveness of the calcitonin gene-related peptide receptor antagonist fremanezumab in chronic and episodic migraine patients [1].

Included in this analysis were 1,494 patients who had received subcutaneous fremanezumab either monthly (225 mg; chronic migraine starting dose of 675 mg), or quarterly (675 mg) at least 12 months. In chronic migraine patients (n=1,110), the mean change in monthly migraine days was -8.1 and -7.2 days in the monthly and quarterly groups, respectively. The ≥50% response rate was 57% and 53%. The number of headache days of at least moderate severity decreased similarly: -6.8 and -6.4 days. In episodic migraine patients (n=780), the mean change in monthly migraine days was -5.1 and -5.2 days in the monthly and quarterly groups, with a ≥50% response rate of 68% and 66%. Headache days of at least moderate severity decreased by -4.2 and -4.4 days. Injection-site reactions, mostly mild to moderate, were the most common adverse events (26-33%). Serious adverse events occurred in 3%; none were treatment-related.

In a separate presentation, the long-term efficacy of fremanezumab was looked at using different response rate thresholds. The results showed that efficacy of fremanezumab was maintained over 12 months, with similar or greater response rates after 1 year than at earlier time points [2].

  1. Goadsby P, et al. AAN 2019, S38.004.
  2. Newman L, et al. AAN 2019, S38.001.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.